
Takeda’s oral TYK2 inhibitor showed rapid skin clearance in phase 3 psoriasis trials as FDA fast-tracks review; decision expected early 2027.
VIDEO: The non-pruritic rash began on his chest and spread rapidly over 3 days. Get a closer look; what's your diagnosis?